Pharmaceutical

STAT+: Raleigh-Durham challenges Boston as biomanufactu...

Like Boston, Raleigh-Durham has elite universities and a talented workforce — pl...

Methadone treatment gets first major update in over 20 ...

To better stave off opioid withdrawal, methadone clinics will be allowed to pres...

Novavax is on thin ice, and the latest update isn’t exa...

Novavax, the company whose corporate missteps repeatedly sidelined an effective ...

STAT+: Pharmalittle: We’re reading about Medicare price...

The Biden administration is making its opening offers to pharmaceutical companie...

STAT+: Biden administration makes opening offers in Med...

Medicare will negotiate discounts for each drug ranging from 25% off list price ...

Opinion: Where do we go from here on digital therapeutics?

Where do we go from here on digital therapeutics?

STAT+: General Catalyst wants to take over a safety-net...

The venture capital firm’s experiment is facing hurdles even before it has start...

STAT+: Can gene therapies make for a profitable busines...

Some takes and thoughts from @adamfeuerstein on Bluebird Bio’s quest for gene th...

Opinion: Why I left the editorial board of the prestigi...

Scientists like Shella Keiholz are beginning to rebel against the unjustifiable ...

STAT+: Obscure vertigo drug could bring rare hope for p...

A patient community that has endured a series of crushing setbacks may soon get ...

Phase III study halted: Ferrer’s oral edaravone disappo...

Ferrer has announced that its FAB122 failed to achieve its primary efficacy and ...

Germany’s Ministry of Health refutes accusations of wor...

Germany’s Federal Ministry of Health has published its evaluation report on the ...

FDA awarded record number of review designations to CRI...

In late 2023, Vertex Pharmaceuticals and CRISPR Therapeutics made history by gai...

Can Musk’s BCI company Neuralink be trusted to put chip...

Musk announced Neuralink's first sucessful human BCI implant on Sunday, but can ...

Astellas seeks approval for Padcev-Keytruda combo thera...

Astellas has submitted an sNDA in Japan seeking approval for PADCEV with KEYTRUD...

CMS sets up negotiating framework for expensive sickle ...

CMS’ CGT Access Model will see allow the agency to negotiate negotiate pricing a...